



## Updates on Mechanism and Management of Gynecological Cancer

Guest Editors:

**Prof. Dr. Giorgio Valabrega**

Department of Oncology,  
University of Turin, Medical  
Oncology, Ordine Mauriziano  
Hospital, Turin, Italy

**Dr. Margherita Turinetti**

Candiolo Cancer Institute, FPO-  
IRCCS, Candiolo, Italy

Deadline for manuscript  
submissions:

**25 August 2024**

### Message from the Guest Editors

Dear Colleagues,

As of late, immunotherapy has been front and center in the development of new strategies for the treatment of endometrial cancer (EC). Up to 30% of new diagnoses and 13 to 30% of recurrent EC are microsatellite instability-high (MSI-H), a clinical setting wherein studies have shown great results, with Dostarlimab showing response rates of 42% (1), Pembrolizumab of 57% (2), and PD-L1 inhibitors such as Durvalumab of 43% (3). In microsatellite-stable (MSS) EC, immune checkpoint inhibitors (ICI) have shown more modest but still present activity, making them worthy of further research. The final efficacy analyses of Pembrolizumab-Lenvatinib in the Keynote 158 trial granted FDA approval of this combination therapy in relapsed MSS EC after progression to first-line chemotherapy. Furthermore, trials featuring ICI in both neoadjuvant and adjuvant settings are ongoing.

In conclusion, this Special Issue welcomes articles that illustrate the mechanisms behind response and resistance to immunotherapy in EC, possible predictive clinical and molecular markers, and novel approaches to immunotherapy such as CAR-T cell therapy and vaccines.





**cancers**



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI